Dr. Garmey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 College Rd E
G P C Biotech
Princeton, NJ 08540Phone+1 609-936-3100
Education & Training
Icahn School of Medicine at Mount SinaiClass of 2001
Certifications & Licensure
NY State Medical License 2005 - 2019
Clinical Trials
- CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) Start of enrollment: 2014 Jul 01
Publications & Presentations
PubMed
- 15 citationsPilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancerJoseph Chao, James Lin, Paul Frankel, Andrew J. Clark, Devin T. Wiley
Journal of Gastrointestinal Oncology. 2017-12-01 - 45 citationsCRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.Xi Tian, Minh Nguyen, Henry P. Foote, Joseph M. Caster, Kyle C. Roche
Cancer Research. 2017-01-01 - 35 citationsEfficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-II...Stephen M. Keefe, Jean H. Hoffman-Censits, Roger B. Cohen, Ronac Mamtani, Daniel F. Heitjan
Annals of Oncology. 2016-08-01
Press Mentions
Chutes & Ladders—Novartis Brings in New CEO to Clean up Korean BranchAugust 24th, 2018- Sensei Brings on New CMO as It Eyes Phase 2 Immuno-Oncology TrialAugust 21st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
